Fear of the risk of recurrence is a reality for many #EarlyBreastCancer survivors and can deeply affect their emotional wellbeing. This #BreastCancerAwarenessMonth emphasizes the value of meeting this fear with empathy, clear communication, and continuous support.

Not all HR+, HER2- early breast cancer has the same #RiskOfRecurrence. Several clinical and biological features may be considered to help support more tailored #BreastCancerCare decisions. Follow us for more updates this #BreastCancerAwarenessMonth.

One patient, one dedicated team. Optimal #BreastCancerCare is strengthened by multidisciplinary collaboration. Coordinating care and following evidence-based standards helps support adherence and improve long-term outcomes. Follow us for more #BreastCancer insights.

Pack your bags! #ESMO2026 is almost here. New data, interactive education, and networking await in Madrid. We cannot wait to be part of the discussions that will help shape the future of #BreastCancerCare.

Younger age at diagnosis has been shown to be an independent factor associated with late distant recurrence in HR-positive, HER2-negative early breast cancer. This #BreastCancerAwarenessMonth let’s remember that #BreastCancerCare should be based on the individual.

Long-term care remains important, even with fewer involved lymph nodes. In ER+ #EBC, understanding #RiskOfRecurrence can support #BreastCancerCare decisions.

This #BreastCancerAwarenessMonth, remember that every day counts when managing #EarlyBreastCancer. Timely risk stratification equips clinical teams to make faster care decisions and build tailored follow-up strategies when they matter most.¹,²

Adherence in #EarlyBreastCancer is shaped by clinical, personal, and socioeconomic factors. This #BreastCancerAwarenessMonth, let's focus on overcoming these barriers to help keep patients on track. How do you build open dialogue early in #BreastCancerCare?

Decades of dedication have driven progress in #BreastCancerCare, bringing 5-year survival rates above 90%. Yet every journey starts with a first step. This #BreastCancerAwarenessMonth, we are reminded that taking early action remains vital to improving patient outcomes.¹,²

In #CLL comorbidity assessment shapes the care plan, but generic tools may not capture what matters most.¹⁻³ What assessment approach do you use in your #CLLCare practice? Share your perspective. #MalignantHematology

Transitioning a patient to a subsequent line of care in #CLL is complex and requires a systematic approach.¹⁻³ Dr. Anna Maria Frustaci discusses how to navigate these clinical transitions effectively to help optimize #CLLCare.

Shared decision-making in #CLL starts with conversation — not assumption.¹ How do you uncover individual patient priorities in your #CLLCare practice? Follow us & join our upcoming webinar on shared decision-making in CLL.

On #WorldLymphomaDay we recognise everyone living with lymphoma, including #CLL and #MCL, and all those working to support them. To the clinicians, researchers, advocates, and patients driving progress: thank you.

How do you define and discuss clinical response in #CLL? Prof. @chanyooncheah reviews the iwCLL guidelines and highlights the importance of separating remission from cure to set realistic, honest goals for long-term #CLLCare.

Patient survey data in #CLL (chronic lymphocytic leukemia) highlights a gap between the desire for involvement in care decisions and the actual experience.¹ How do you address this in your #CLLCare practice? #MalignantHematology

How do you explain "watch and wait" to newly diagnosed #CLL patients without sounding passive? Dr. Lydia Scarfò discusses reframing observation as a proactive "monitor and move on" strategy to alleviate anxiety.¹

What is the greatest barrier to shared decision-making in your hematology/oncology practice?

Which factor has the most impact on patients’ quality of life during CLL treatment in your experience?

How do you keep yourself up-to-date about novel findings in CLL and MCL?

As the #EHA2026 conference comes to a close, we would like to thank everyone who made it special. We truly valued the insightful discussions at our booth! Lilly will continue to strive towards better care for individuals with a #HematologicalMalignancy.